Pharmacyclics Receives “Neutral” Rating from Zacks (PCYC)
Pharmacyclics (NASDAQ:PCYC)‘s stock had its “neutral” rating reiterated by Zacks in a research note issued on Monday, Analyst Ratings Network reports. They currently have a $142.00 price objective on the stock. Zacks‘ target price suggests a potential upside of 5.03% from the company’s current price.
Zacks‘ analyst wrote, “The approval of Imbruvica for treating MCL patients in Nov 2013 is a positive for Pharmacyclics. However, Imbruvica’s commercial potential for MCL is limited, given the small target population. We expect approval of the drug for the more lucrative CLL/SLL indication by Feb 28, 2014. Imbruvica is also being evaluated for other oncology indications by Pharmacyclics and partner Johnson & Johnson. We expect investor focus to remain on Imbruvica updates. We believe that the company must expand its pipeline to reduce dependence on Imbruvica. We are initiating coverage on the stock with a Neutral recommendation as the scope for appreciation from current levels appears limited until further visibility is obtained on Imbruvica’s initial sales. “
Shares of Pharmacyclics (NASDAQ:PCYC) traded down 7.99% on Monday, hitting $124.404. 825,905 shares of the company’s stock traded hands. Pharmacyclics has a 1-year low of $66.97 and a 1-year high of $145.30. The stock’s 50-day moving average is $118.8 and its 200-day moving average is $118.8. The company has a market cap of $9.170 billion and a P/E ratio of 228.76.
PCYC has been the subject of a number of other recent research reports. Analysts at Nomura initiated coverage on shares of Pharmacyclics in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Separately, analysts at WallachBeth Capital initiated coverage on shares of Pharmacyclics in a research note to investors on Wednesday, December 18th. They set a “hold” rating and a $108.00 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Pharmacyclics from $125.00 to $150.00 in a research note to investors on Tuesday, December 3rd. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Pharmacyclics currently has a consensus rating of “Buy” and a consensus target price of $142.88.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.